UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2016
Commission File Number: 001-32001
Aptose Biosciences Inc.
(Translation of registrant's name into English)
5955 Airport Road, Suite 228
Mississauga, ON
L4V 1R9
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On February 18, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated February 18, 2016
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Aptose Biosciences Inc. | ||
(Registrant) | ||
Date: February 18, 2016 | /s/ Gregory K. Chow | |
Gregory K. Chow | ||
Senior Vice President and Chief Financial Officer | ||
EXHIBIT 99.1
Aptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference
SAN DIEGO and TORONTO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the 2016 RBC Capital Markets Global Healthcare Conference at 10:00 a.m. ET on Wednesday, February 24, 2016 in New York City.
A live webcast of the fire-side chat can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/74205320763.cfm
The audio webcast will be archived shortly after the live event and will be available for 30 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences Inc.
Greg Chow, CFO
647-479-9828
gchow@aptose.com
BCC Partners
Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
kbergman@bccpartners.com or spietropaolo@bccpartners.com